Loading
Loading
Research Overview
11-amino-acid peptide derived from the prohormone region of preprodopamine; proposed direct neurotrophic action on dopaminergic neurons in preclinical Parkinson's-model paradigms via mechanisms not fully characterised.
Overview
DNSP-11 is a short peptide sequence found in the prohormone region of the dopamine precursor preprodopamine. Preclinical research has investigated whether this naturally-derived sequence possesses neurotrophic or neuroprotective properties toward dopaminergic neurons — the neuronal population that degenerates in Parkinson's disease.
Animal model research has used dopaminergic neurotoxicity paradigms (such as 6-OHDA and MPTP models) to examine whether DNSP-11 administration affects dopaminergic neuron survival, dopamine turnover, and behavioural outcomes related to motor function. The proposed mechanism involves direct neurotrophic action on dopaminergic cell populations.
DNSP-11 is a highly experimental compound with no standardised human dosing protocol and no published human safety data. Its extremely short plasma half-life (minutes) and the use of intracranial routes in some animal studies present significant barriers to translational research.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, dnsp-11 has no TGA approval for therapeutic use. It is sold by Capital Precision Labs strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
11-amino-acid peptide derived from the prohormone region of preprodopamine; proposed direct neurotrophic action on dopaminergic neurons in preclinical Parkinson's-model paradigms via mechanisms not fully characterised.
Support
For research use only. Capital Precision Labs products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.